COVID-19: Прививки
Назад
Из регулярного британского отчёта:
Figure 6 shows monthly categorised Roche S levels in N-antibody negative individuals by age group. Almost all tested S-antibody negative during December. In the 3 oldest age groups, the impact of first vaccine dose, then second vaccine dose, can be seen from December through be seen from December through June, as the profile of population antibody levels increases. Then from June through September the profile of antibody levels in these cohorts gradually decreases, consistent with waning. During October there is a small increase in percentage of donors with high antibody levels of 1000+ AU/ml for the 70 to 84 age group only, following the initiation of the booster programme. The higher profile of antibody levels in the youngest age group, is likely a result of a combination of factors including stronger immune responses in younger individuals and the higher antibody levels produced after mRNA vaccination.
Это титры антител к спайку у неболевших, но привитых.
Figure 7 shows categorised Roche S levels in N-antibody positive individuals, those likely to have experienced past infection. Pre-vaccination antibody levels will be influenced by time since infection, variant and severity of infection, as well as personal factors such as underlying health conditions and age. At the start of the vaccination rollout in December antibody levels typically sat within the range of 0.8 to 1000 AU/ml, after vaccination antibody levels typically exceed 1000 AU/ml. Comparing Figure 6 with Figure 7, the overall higher profile of antibody levels in those who have experienced past infection is evident; both vaccination post infection and breakthrough infection following vaccination are expected to boost existing antibody levels.
А это титры антител к спайку у переболевших. Как мы видим титры переболевших намного выше.
https://assets.publishing.service.gov.uk/government/upload...
